Noncanonical EF-hand motif strategically delays Ca2+ buffering to enhance cardiac performance

Nature Medicine

Volumn 19, Issue 3, 2013, Pages 305-312

  Wang, Wang ^a,d   Barnabei, Matthew S ^a   Asp, Michelle L ^a   Heinis, Frazer I ^a   Arden, Erik ^a   Davis, Jennifer ^a,d,e   Braunlin, Elizabeth ^a   Li, Qi ^b   Davis, Jonathan P ^c   Potter, James D ^b   Metzger, Joseph M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; GLUTAMIC ACID; GLUTAMINE; MAGNESIUM; PARVALBUMIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CALCIUM CELL LEVEL; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; FEMALE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEART PERFORMANCE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; RAT;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; CALMODULIN; EF HAND MOTIFS; FEMALE; HEART; MAGNESIUM; MALE; MOLECULAR SEQUENCE DATA; MUSCLE CONTRACTION; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; PARVALBUMINS; PROTEIN STRUCTURE, TERTIARY; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SEQUENCE ALIGNMENT;

EID: 84875225507     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3079     Document Type: Article

References (70)

1. Clapham, D.E. Calcium signaling. Cell 131, 1047-1058 (2007).
2. Bers, D.M. Cardiac excitation-contraction coupling. Nature 415, 198-205 (2002).
3. 2+ cycling. Annu. Rev. Med. 59, 13-28 (2008).
4. Kass, D.A., Bronzwaer, J.G. & Paulus, W.J. What mechanisms underlie diastolic dysfunction in heart failure? Circ. Res. 94, 1533-1542 (2004).
5. 2+ handling in heart failure. J. Clin. Invest. 115, 556-564 (2005).
6. MacLennan, D.H. & Kranias, E.G. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4, 566-577 (2003).
7. Periasamy, M. & Janssen, P.M. Molecular basis of diastolic dysfunction. Heart Fail. Clin. 4, 13-21 (2008).
8. Zile, M.R., Baicu, C.F. & Gaasch, W.H. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N. Engl. J. Med. 350, 1953-1959 (2004).
9. Minamisawa, S. et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99, 313-322 (1999).
10. 2+-ATPase in patients with advanced heart failure. Circulation 124, 304-313 (2011).
11. Kho, C. et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature 477, 601-605 (2011).
12. Wang, W. & Metzger, J.M. Parvalbumin isoforms for enhancing cardiac diastolic function. Cell Biochem. Biophys. 51, 1-8 (2008).
13. 2+-binding helix-loop-helix EF-hand motifs. Biochem. J. 405, 199-221 (2007).
14. Heizmann, C.W. Parvalbumin, an intracellular calcium-binding protein; distribution, properties and possible roles in mammalian cells. Experientia 40, 910-921 (1984).
15. Kretsinger, R.H. & Nockolds, C.E. Carp muscle calcium-binding protein. II. Structure determination and general description. J. Biol. Chem. 248, 3313-3326 (1973).
16. 2+-binding proteins parvalbumin and oncomodulin and their genes: new structural and functional findings. Biochim. Biophys. Acta 1306, 39-54 (1996).
17. Falke, J.J., Drake, S.K., Hazard, A.L. & Peersen, O.B. Molecular tuning of ion binding to calcium signaling proteins. Q. Rev. Biophys. 27, 219-290 (1994).
18. Strynadka, N.C. & James, M.N. Crystal structures of the helix-loop-helix calcium-binding proteins. Annu. Rev. Biochem. 58, 951-998 (1989).
19. Declercq, J.P., Tinant, B., Parello, J. & Rambaud, J. Ionic interactions with parvalbumins. Crystal structure determination of pike 4.10 parvalbumin in four different ionic environments. J. Mol. Biol. 220, 1017-1039 (1991).
20. 2+ coordination, by genetic engineering. J. Biol. Chem. 267, 15469-15474 (1992).
21. 2+-binding sites of calmodulin. J. Biol. Chem. 267, 5286-5295 (1992).
22. Rome, L.C. Design and function of superfast muscles: new insights into the physiology of skeletal muscle. Annu. Rev. Physiol. 68, 193-221 (2006).
23. Hirsch, J.C. et al. Comparative analysis of parvalbumin and SERCA2a cardiac myocyte gene transfer in a large animal model of diastolic dysfunction. Am. J. Physiol. Heart Circ. Physiol. 286, H2314-H2321 (2004).
24. Coutu, P. & Metzger, J.M. Optimal range for parvalbumin as relaxing agent in adult cardiac myocytes: gene transfer and mathematical modeling. Biophys. J. 82, 2565-2579 (2002).
25. Coutu, P., Bennett, C.N., Favre, E.G., Day, S.M. & Metzger, J.M. Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked α-tropomyosin mutations. Circ. Res. 94, 1235-1241 (2004).
26. Wahr, P.A., Michele, D.E. & Metzger, J.M. Parvalbumin gene transfer corrects diastolic dysfunction in diseased cardiac myocytes. Proc. Natl. Acad. Sci. USA 96, 11982-11985 (1999).
27. 2+ buffering action. Physiol. Genomics 33, 312-322 (2008).
28. Johnson, J.D., Jiang, Y. & Rall, J.A. Intracellular EDTA mimics parvalbumin in the promotion of skeletal muscle relaxation. Biophys. J. 76, 1514-1522 (1999).
29. Putkey, J.A., Sweeney, H.L. & Campbell, S.T. Site-directed mutation of the trigger calcium-binding sites in cardiac troponin C. J. Biol. Chem. 264, 12370-12378 (1989).
30. Negele, J.C., Dotson, D.G., Liu, W., Sweeney, H.L. & Putkey, J.A. Mutation of the high affinity calcium binding sites in cardiac troponin C. J. Biol. Chem. 267, 825-831 (1992).
31. Yang, J.J., Gawthrop, A. & Ye, Y. Obtaining site-specific calcium-binding affinities of calmodulin. Protein Pept. Lett. 10, 331-345 (2003).
32. Cates, M.S. et al. Metal-ion affinity and specificity in EF-hand proteins: coordination geometry and domain plasticity in parvalbumin. Structure 7, 1269-1278 (1999).
33. Hutnik, C.M., MacManus, J., Banville, D. & Szabo, A. Comparison of metal ion-induced conformational changes in parvalbumin and oncomodulin as probed by the intrinsic fluorescence of tryptophan 102. J. Biol. Chem. 265, 11456-11464 (1990).
34. Schwartz, A. Methods in Pharmacology: Myocardial Biology Vol. 5, 63-75 (Plenum Press, New York, 1984).
35. Rodenbaugh, D.W. et al. Parvalbumin isoforms differentially accelerate cardiac myocyte relaxation kinetics in an animal model of diastolic dysfunction. Am. J. Physiol. Heart Circ. Physiol. 293, H1705-H1713 (2007).
36. Harrison, S.M. & Bers, D.M. Modification of temperature dependence of myofilament Ca sensitivity by troponin C replacement. Am. J. Physiol. 258, C282-C288 (1990).
37. McKillop, D.F. & Geeves, M.A. Regulation of the interaction between actin and myosin subfragment 1: evidence for three states of the thin filament. Biophys. J. 65, 693-701 (1993).
38. 2+-saturated form. Nature 424, 35-41 (2003).
39. Hoffmann, B., Schmidt-Traub, H., Perrot, A., Osterziel, K.J. & Gessner, R. First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Hum. Mutat. 17, 524 (2001).
40. Schmidtmann, A. et al. Cardiac troponin C-L29Q, related to hypertrophic cardiomyopathy, hinders the transduction of the protein kinase A dependent phosphorylation signal from cardiac troponin I to C. FEBS J. 272, 6087-6097 (2005).
41. Baryshnikova, O.K., Li, M.X. & Sykes, B.D. Modulation of cardiac troponin C function by the cardiac-specific N-terminus of troponin I: influence of PKA phosphorylation and involvement in cardiomyopathies. J. Mol. Biol. 375, 735-751 (2008).
42. Dzimiri, N. Regulation of β-adrenoceptor signaling in cardiac function and disease. Pharmacol. Rev. 51, 465-501 (1999).
43. Bristow, M.R. et al. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N. Engl. J. Med. 307, 205-211 (1982).
44. Townsend, D. et al. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol. Ther. 15, 1086-1092 (2007).
45. Andersson, K.B. et al. Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene. J. Mol. Cell Cardiol. 47, 180-187 (2009).
46. Mogensen, J. et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J. Clin. Invest. 111, 209-216 (2003).
47. 2+-independent mechanical tone and acute myocyte remodeling. Circ. Res. 100, 1494-1502 (2007).
48. Davis, J. et al. Diastolic dysfunction and thin filament dysregulation resulting from excitation-contraction uncoupling in a mouse model of restrictive cardiomyopathy. J. Mol. Cell Cardiol. 53, 446-457 (2012).
49. Kawasaki, H. & Kretsinger, R.H. Calcium-binding proteins 1: EF-hands. Protein Profile 2, 297-490 (1995).
50. Marsden, B.J., Shaw, G.S. & Sykes, B.D. Calcium binding proteins. Elucidating the contributions to calcium affinity from an analysis of species variants and peptide fragments. Biochem. Cell Biol. 68, 587-601 (1990).
51. Kitzman, D.W. & Daniel, K.R. Diastolic heart failure in the elderly. Heart Fail. Clin. 3, 437-453 (2007).
52. Lorell, B.H. Significance of diastolic dysfunction of the heart. Annu. Rev. Med. 42, 411-436 (1991).
53. Mann, D.L. Heart Failure: A Companion to Braunwald's Heart Disease. Chap. 7 (Elsevier Health Sciences, 2004).
54. Tang, W.H. & Francis, G.S. The year in heart failure. J. Am. Coll Cardiol. 52, 1671-1678 (2008).
55. Ingwall, J.S. & Weiss, R.G. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ. Res. 95, 135-145 (2004).
56. Westfall, M.V., Rust, E.M., Albayya, F. & Metzger, J.M. Adenovirus-mediated myofilament gene transfer into adult cardiac myocytes. Methods Cell Biol. 52, 307-322 (1997).
57. 2+ binding to calmodulin. Methods Enzymol. 102, 135-143 (1983).
58. Guan, K.L. & Dixon, J.E. Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Anal. Biochem. 192, 262-267 (1991).
59. Tikunova, S.B. & Davis, J.P. Designing calcium-sensitizing mutations in the regulatory domain of cardiac troponin C. J. Biol. Chem. 279, 35341-35352 (2004).
60. Coutu, P. & Metzger, J.M. Genetic manipulation of calcium-handling proteins in cardiac myocytes. I. Experimental studies. Am. J. Physiol. Heart Circ. Physiol. 288, H601-H612 (2005).
61. 2+ transport ATPase of sarcoplasmic reticulum. J. Biol. Chem. 252, 8567-8571 (1977).
62. Puglisi, J.L., Bassani, R.A., Bassani, J.W., Amin, J.N. & Bers, D.M. Temperature and relative contributions of Ca transport systems in cardiac myocyte relaxation. Am. J. Physiol. 270, H1772-H1778 (1996).
63. Stein, R.B., Gordon, T. & Shriver, J. Temperature dependence of mammalian muscle contractions and ATPase activities. Biophys. J. 40, 97-107 (1982).
64. 2+ dissociation rates from parvalbumin of frog muscle fibres. J. Physiol. (Lond.) 449, 399-410 (1992).
65. Herron, T.J. et al. Calcium-independent negative inotropy by β-myosin heavy chain gene transfer in cardiac myocytes. Circ. Res. 100, 1182-1190 (2007).
66. 2+ cycling. Circ. Res. 100, 96-104 (2007).
67. Metzger, J.M. Myosin binding-induced cooperative activation of the thin filament in cardiac myocytes and skeletal muscle fibers. Biophys. J. 68, 1430-1442 (1995).
68. 2+-independent positive molecular inotropy for failing rabbit and human cardiac muscle by α-myosin motor gene transfer. FASEB J. 24, 415-424 (2010).
69. Maddaford, T.G., Hurtado, C., Sobrattee, S., Czubryt, M.P. & Pierce, G.N. A model of low-flow ischemia and reperfusion in single, beating adult cardiomyocytes. Am. J. Physiol. 277, H788-H798 (1999).
70. Day, S.M. et al. Histidine button engineered into cardiac troponin I protects the ischemic and failing heart. Nat. Med. 12, 181-189 (2006).